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Abstract
Objectives: Published cost estimates for cystic fibrosis (CF) are based on older data and do not 
reflect increased use of specialty drugs in recent years. We assessed recent trends in healthcare 
expenditures for CF patients in the United States (US) with employer-sponsored health insurance.
Methods: The study is a retrospective analysis of claims data for privately insured individuals 
aged 0–64 years who were continuously enrolled in non-capitated plans for at least 1 calendar year 
during 2010–2016. Mean annual expenditures during a calendar year were calculated for 
individuals who met a claims-based CF case definition. Average annual growth rates were 
calculated through linear regression of the natural logarithm of annual expenditures.
Results: The annual CF prevalence was 1.1–1.4 per 10 000 adults and 2.9–3.0 per 10 000 
children. Average spending adjusted for inflation nearly doubled from roughly $67 000 per patient 
in 2010 and 2011 to approximately $131 000 per patient in 2016. Inflation-adjusted spending on 
outpatient and inpatient care increased by 0.5% and 2.5% per year, respectively, whereas 
pharmaceutical spending increased by 20.2% per year. Virtually all of the growth in 
pharmaceutical spending was accounted for by spending on specialty drugs; inflation-adjusted 
spending on other medications increased by 1.3% per year. The annual growth rate in 
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pharmaceutical spending rose by 33.1% during 2014–2016, the years during which lumacaftor/
ivacaftor was introduced.
Conclusions: Per-patient expenditures for privately-insured patients with CF almost doubled 
during 2010–2016; specialty drugs were largely responsible for this increase, with a major 
contribution from new, genotype-targeted CFTR modulator medications.
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1 | INTRODUCTION
Up-to-date estimates of healthcare expenditures for US patients with cystic fibrosis (CF) are 
lacking. Expenditures per patient with CF with enrolled in fee-for-service employer-
sponsored insurance (ESI) plans during 2006 averaged $48 098, with a median of $30 508.1 
Rising healthcare expenditures in the United States have been paced by spending on 
prescription medications, which in 2015 accounted for 17% of aggregate expenditures.2 Cost 
estimates used in economic evaluations of CF therapies should reflect up-to-date clinical 
practices.
Much pharmaceutical spending is on specialty drugs, defined in the US context as 
medications costing at least $1000 per prescription or per month.3 Specialty drugs include 
orphan drugs that target rare diseases such as CF, which affects about 35 000 people in the 
United States.4 Specialty drugs for CF include pulmonary medications that treat chronic 
infection, airway mucus obstruction, and inflammation, and pancreatic enzyme products to 
treat malabsorption. Until recently, pancreatic enzymes as nutritional supplements were 
unregulated in the United States. After the U.S. Food and Drug Administration (FDA) began 
to require approval of marketing of pancreatic enzyme products on the basis of evidence of 
clinical efficacy and safety, FDA approved six pancreatic enzyme products for CF during 
2009–2012.5
CF has become a model system for precision medicine, which includes medications targeted 
to specific protein defects associated with individual mutations or genotypes.6 In particular, 
new genome-specific biologic medications, namely cystic fibrosis transmembrane 
conductance regulator (CFTR) modulator therapies that target defects in the CFTR protein 
caused by specific mutations in the CFTR gene, have been introduced. Ivacaftor 
(Kalydeco™) was first approved by FDA in January 2012 for patients aged ≥6 years with a 
G551D CFTR mutation, about 4–5% of CF patients.7,8 FDA subsequently expanded its 
approved use to include nine additional mutations (February 2014), patients ≥2 years old 
(March 2015) and, most recently, an additional 23 mutations (May 2017).9 Uptake of 
ivacaftor use following FDA approval was rapid, with roughly 80% of eligible patients 
initiating use in the first year.10 A combination drug, lumacaftor/ivacaftor (Orkambi™) was 
approved in July 2015 for patients aged ≥12 years with the most common CFTR genotype 
(delF508 homozygous),11 and the indication was expanded in 2016 to children aged 6–11 
years. These two approved CFTR medications are an order of magnitude more expensive 
than other CF specialty drugs.11 No studies have reported the contribution of spending on 
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these products to overall expenditures for insured patients with CF, although one modeling 
study was published in 2016.12 In this study, we describe current trends in health care 
expenditures for commercially insured patients with CF in the US.
2 | METHODS
2.1 | Data source
The IBM Watson Truven Health MarketScan® Commercial Database is a nationwide 
convenience sample of claims data from ESI plans. Numerous peer-reviewed articles have 
used those data, including two CF cost studies published in this journal.1,13 Participating 
plans, both capitated and non-capitated, are of two types; large, self-insured employers that 
contract with plans to administer payments, and health plans that sell insurance to smaller, 
fully-insured employers.
We accessed the MarketScan data via Treatment Pathways 4.0, an online analytic platform 
using a dynamic version of the data that is stored on IBM Watson servers and is regularly 
updated. Specifically, on December 31, 2017, we accessed the 100% Treatment Pathways 
sample of data from January 1, 2010 through July 31, 2017. Treatment Pathways is restricted 
to plans with prescription drug coverage. Those plans include roughly 75% of all 
MarketScan enrollees. Treatment Pathways combines data from the MarketScan 
Commercial and Medicare Supplemental databases. MarketScan data are deidentified, and 
their analysis is not classified by the Centers for Disease Control and Prevention as human 
subjects research. Truven Health Analytics, which is an IBM Company, maintains data 
validity and integrity.
2.2 | Data analysis
We analyzed data on patients with CF who were continuously enrolled in non-capitated 
plans for at least 1 calendar year during 2010–2016 and were aged 0–64 years at the 
beginning of a calendar year. We identified patients with CF using an algorithm that required 
either one inpatient claim with an International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9-CM) diagnosis code of 277.0× or International Classification 
of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code of E84x 
(Supplemental Table S1) or two outpatient claims with the same set of codes at least 30 days 
apart between January 1, 2010 and July 31, 2017.
Expenditures were calculated by calendar year from 2010 through 2016 and restricted to 
patients with continuous enrollment during the calendar year. Patients were classified as 
pediatric if they were reported to be aged ≤17 years at the beginning of the calendar year and 
adults were those aged 18–64 years.
Annual mean and median expenditures were calculated for all health care services, with or 
without a CF code, and mean expenditures were calculated separately for inpatient services, 
outpatient services, and outpatient pharmaceuticals. Prescription expenditures were further 
stratified into four groups: ivacaftor, lumacaftor/ivacaftor, other CF-specific specialty drugs 
(pulmonary medications and pancreatic enzyme products), and all other pharmaceuticals 
(Supplemental Table S2). Outpatient expenditures were classified in this analysis into 
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outpatient encounters, emergency room (with discharge home), laboratory tests, and durable 
medical equipment for respiratory support.
Per-person mean current calendar-year expenditures were calculated and graphed. Average 
annual growth rates were calculated through linear regression of the natural logarithm of 
annual mean or median expenditures on calendar year for specified time periods; the 
regression coefficient expresses the average exponential increase for that period.14 Growth 
rates were calculated for the entire 2010–016 period and for sub-periods determined with 
regard to inflection points ascertained through visual inspection of the data.
In addition to current-year expenditures, mean and median expenditures were calculated in 
constant-year terms (expressed in 2016 US dollars) through two different methods of 
inflation adjustment. First, the total personal consumption expenditures (PCE) index of the 
US Bureau of Economic Analysis was used to adjust expenditures from different years to 
overall purchasing power. Second, the PCE healthcare index by function was used to adjust 
expenditures for medical inflation. The latter measure is an unbiased measure of medical 
inflation, whereas the commonly used medical care component of the Consumer Price Index 
has consistently overstated the rate of overall medical inflation.15
3 | RESULTS
3.1 | Population characteristics
Numbers of unique MarketScan enrollees ≤64 years with continuous enrollment in non-
capitated plans with prescription drug coverage during a calendar year peaked at 25.8 
million in 2012 and declined to 15.6 million in 2016. In each year, 24–26% of the sample 
were aged ≤17 years. Most of the decline after 2012 was in the category of fully-insured 
health plans sponsored by smaller employers. Numbers enrolled in large, self-insured 
employer plans during a calendar year was 14.6 million (57% of total enrollment) in 2012 
and 12.3 million (79% of total enrollment) in 2016.
The number of unique individuals in the database with continuous enrollment in non-
capitated plans by calendar year varied from 18 million to 28 million. The number of 
patients within each year’s defined cohort who had ≥2 outpatient claims or ≥1 inpatient 
claim associated with CF within the calendar year varied from 2745 to 4291. The ratio of the 
two numbers is the administrative prevalence of CF in the subsample of persons 
continuously-enrolled in non-capitated plans. The annual administrative prevalence was 1.1–
1.4 per 10 000 working-age adults and 2.8–3.0 per 10 000 children each year from 2010 
through 2016 (Table 1). The administrative prevalence in children was similar to the birth 
prevalence of CF in the United States, estimated at 2.9 per 10 000 births.4 The lower 
frequency of CF in adults in this sample is a product of both excess mortality and sample 
selection for relatively healthy adults with ESI.
3.2 | Overall expenditures
Spending per patient at current prices grew rapidly between 2010 and 2016. Median 
expenditures increased from $32 586 in 2010 to $67 760 in 2016, more than doubling in a 
period of 5 years (Table 2). Similarly mean expenditures more than doubled at current 
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prices, from $61 591 to $130 879. Expenditures were lower for pediatric patients, for 
example, median $62 014 and mean $116 171 in 2016, than for adult patients, median $72 
846 and mean $140 564.
Mean expenditures began to increase substantially in 2012 and even more rapidly beginning 
in 2015 (Figure 1). The annual exponential growth in mean expenditures during 2010–2016 
was 12.2% in current dollars, 10.8% relative to general prices, and 10.6% relative to medical 
prices. The exponential growth rates in median expenditures were slightly lower, 11.7%, 
10.3%, and 10.2%, respectively.
Changes over time in per-patient expenditures were similar for self-insured and fully-insured 
plans. The ratio of mean expenditures between fully-insured and self-insured plans was 1.00 
in 2010 and 0.96 in 2016 and fluctuated in the range 0.86–1.05. Greater variability occurred 
in the ratios of mean expenditures by age group across years, 0.89–1.15 for the pediatric 
sample and 0.79–1.10 for the adult sample.
Per-person spending on inpatient care and non-pharmaceutical outpatient care grew 
relatively modestly. From 2010 to 2016, inpatient spending increased in current dollars by 
3.2% per year and outpatient spending by 2.5% per year. The average changes in constant-
dollar per-person spending were 1.8% per year for inpatient services and 1.1% per year for 
outpatient non-pharmaceutical services relative to general consumer prices (Table 3) and by 
1.7% and 1.0% per year relative to medical prices.
3.3 | Pharmaceutical expenditures
Most of the growth in per-person expenditures was in the category of outpatient 
pharmaceuticals, which grew by 21.8% per year in current dollars and by 20.2–20.4% per 
year in constant dollars. The share of pharmaceuticals in total spending increased from 
35.8% in 2010 to 64.1% in 2016. The pharmaceutical share of spending was highest for 
children and adolescents, 39.3% in 2010 and 68.4% in 2016. The increase in pharmaceutical 
spending was not steady over time. During 2011–2014 the annual growth rate in inflation-
adjusted prescription payments was 16.5–16.7%; that rate more than doubled to 33.7–34.2% 
during 2014–2016.
Changes in spending by type of medication for the whole sample are shown in Figure 2. 
Virtually all of the growth in pharmaceutical spending was accounted for by growth in 
spending on specialty drugs, including the new CFTR modulators. Spending on all other 
medications grew by just 1.6% per year in real terms, with the share of drug spending 
accounted for by non-specialty medications falling from 29% in 2010 to 8% in 2016.
Ivacaftor accounted for 15–19% of drug spending each year from 2012 through 2016. 
Among the 5.8% of CF patients who took ivacaftor in 2016, the drug accounted for 85% of 
pharmaceutical spending. Lumacaftor/ivacaftor accounted for 19% of all pharmaceutical 
spending for the CF population in 2015 and 34% in 2016. In 2016, lumacaftor/ivacaftor was 
taken by 17.6% of CF patients in this sample, and it accounted for 74% of their total 
pharmaceutical spending. Excluding spending on CFTR modulators, the average annual 
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growth in inflation-adjusted spending per privately insured patient with CF was 4.8%, 
compared with 10.8% annual growth in overall inflation-adjusted spending.
Growth in spending on other specialty drugs, both pulmonary and pancreatic, was also rapid. 
Inflation-adjusted spending on pancreatic enzyme and pulmonary therapies grew by 17.1–
17.3% and 9.1–9.2% per year, respectively. Because growth in spending on CFTR 
modulators was even more rapid, the share of other specialty drugs fell from 72% of 
pharmaceutical spending in 2010 (56% for pulmonary drugs and 16% for pancreatic 
enzymes) to 42% in 2016 (28% for pulmonary and 14% for pancreatic enzymes).
The increases in per-patient spending on pancreatic enzyme and pulmonary products were 
largely accounted for by increased spending per filled prescription, which grew in inflation-
adjusted terms by 12.8% and 7.4% per year. There were modest increases in the proportions 
of patients using pancreatic enzymes or pulmonary medications, from 54% and 55% in 2010 
to 62% and 60% in 2016, respectively and also modest increases in the number of filled 
prescriptions per user. For pancreatic enzymes, there was a one-time jump from 4.0 fills per 
user in 2010 to 5.1 in 2011.
4 | DISCUSSION
Reported per-patient mean expenditures for privately-insured patients with CF enrolled in 
non-capitated employer-sponsored plans in the United States almost doubled in inflation-
adjusted dollars during the study years, from $67 127 in 2010 to $130 879 in 2016. The 
comparable figure for 2006 per-person mean expenditures 1 in 2016 dollars adjusted for 
general price inflation was $56 252. Growth in median expenditures was similarly rapid, 
from $35 515 in 2010 to $67 760 in 2016. The mean expenditure for the patient population 
is appropriate for assessing aggregate expenditures, whereas the median is useful for 
characterizing costs for typical patients.1
The remarkably rapid growth in per-person expenditures in recent years for the privately 
insured US population living with CF calls into question the continued use of published cost 
estimates derived from time periods when new therapies were either unavailable or were less 
commonly used. Simply adjusting estimates from previous years for inflation is not 
sufficient; current treatment costs for this population requires up-to-date real-world data on 
expenditures. The present study only applies to the privately insured population with ESI 
enrolled in non-capitated plans, who comprise about 85% of the MarketScan Commercial 
sample. The key limitation of the study is that it would not be valid to extrapolate from 
trends in expenditures for privately insured patients with CF to healthcare costs for the 
overall population with CF. Since public payer reimbursements are substantially lower,16 a 
similar analysis of healthcare expenditures for publicly insured patients with CF would also 
provide important information.
Most of the increase in per-person expenditures for privately insured patients with CF since 
2010 was accounted for by increased spending on CF-specific specialty drugs (CFTR 
modulators, pulmonary medications, and pancreatic enzyme products). Excluding such 
products, inpatient and outpatient spending rose by 1–2% per year, respectively, relative to 
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inflation. Pharmaceutical spending rose from one-third of all spending on CF care during 
20061 and 36% in 2010 to 64% in 2016. In particular, the CFTR modulators, although taken 
by a subset of patients, dominated overall growth in spending after 2014. During 2016, 
CFTR modulators were taken by almost one-fourth of privately insured patients with CF and 
accounted for over one-half of all reported drug spending for the CF patient population with 
ESI. More than one-half of all growth between 2010 and 2016 in inflation-adjusted spending 
for privately insured patients with CF was accounted for by spending on CFTR modulators.
The role of specialty drugs as cost drivers in overall healthcare spending has attracted 
growing attention from stakeholders including insurers, self-insured employers, pharmacy 
benefit managers, and public policymakers.3,17 In 2015, specialty drugs accounted for 
almost 40% of drug spending in the United States, and is expected to reach 50% by 2018.17 
The increase in spending has ramifications for insurance benefit design, drug formularies, 
and coverage criteria. The high cost of treatments could also increase out-of-pocket 
spending for patients, which have implications for adherence to therapies and treatment 
decision-making.
Despite the notable increase in specialty drug spending for people with CF, it is important to 
consider the improvements in health outcomes that occurred during this period. Life 
expectancy continues to rise with the introduction of new therapies and advances in care 
delivery. Over the past decade, the CF Foundation has issued peer-reviewed, evidence-based 
guidelines for chronic respiratory medications that support early use of CF-specific specialty 
medications.18 Long-term use of specialty drugs, such as inhaled tobramycin and dornase 
alfa, has been linked to decreased mortality.19 In addition, CF care centers adopting more 
aggressive monitoring in their patient populations have been shown to have better overall 
health outcomes.20 Over this period, therefore, treatment complexity in CF has increased in 
both pediatric and adult patient populations.21 Notably, a recent registry-based comparison 
of CF health outcomes found that children and young adults in the United States had better 
lung function than those in the United Kingdom, and that specialty drugs, such as dornase 
alfa, were much more commonly prescribed in the United States.22 All of these factors that 
have improved health likely also contributed to the rise in pharmaceutical expenditures 
observed in this analysis.
Breakthrough drugs, such as ivacaftor, represent both the greatest promise for dramatic 
improvement in CF health outcomes and the largest impact on healthcare spending. Both 
ivacaftor and lumacaftor/ivacaftor have proven efficacy in clinical trials, although the 
magnitude of clinical benefit in eligible populations in terms of improved lung function is 
greater for ivacaftor monotherapy than for lumacaftor/ivacaftor.8,23 Effectiveness studies 
using real-world patient registry data have shown sustained benefits of ivacaftor in terms of 
slowing disease progression and improving nutritional status.24 An analysis of MarketScan 
claims data found a two-thirds reduction in inpatient admissions with a CF diagnosis among 
patients who initiated ivacaftor therapy during 2012.25
Currently up to one-half of the CF population is eligible for ivacaftor or lumacaftor/
ivacaftor. Additional modulators are in clinical development and, if they are found to be 
efficacious, will be made available to patients with a broader array of genotypes. The long-
Grosse et al. Page 7
Pediatr Pulmonol. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
term impact of the therapies—physiological, healthcare use, survival, and health-related 
quality of life—is still unknown. Ongoing evaluation of these therapies is needed to ensure 
that increased spending on them is associated with optimal outcomes (i.e., the value 
proposition).
Researchers are expected to provide information on costs and outcomes to payers and other 
stakeholders so that decision makers can determine which clinical services provide good 
value.26 The UK National Health Service (NHS) in 2012 commissioned a health technology 
assessment of ivacaftor.27 The incremental cost-effectiveness ratio (ICER) was calculated to 
be 10–15 times higher than the threshold range used, but within the range of other “ultra-
orphan” medicines covered by the NHS.28 On that basis, ivacaftor was approved for 
coverage.
Like any study using administrative healthcare data, this study has limitations.29 One is the 
restriction to a convenience sample of private insurance plans sponsored by employers. The 
MarketScan Commercial data have been found to be comparable in demographics to the US 
population with ESI,30 which in turn comprises >90% of the US population with private 
insurance.31 It has been reported that 56% of a representative US sample of children with CF 
had private insurance.32 MarketScan claims data have previously been analyzed for 
information on expenditures for privately-insured patients with CF.1,13 The study findings, 
however, cannot be extrapolated to people with private plans that do not include prescription 
drugs.
A second limitation is the use of ICD diagnosis codes to identify persons with CF, since ICD 
codes are subject to multiple types of errors.33 Consequently, some people without CF might 
have been incorrectly coded as having CF. An algorithm of ≥2 outpatient claims on separate 
dates or ≥1 inpatient claim is commonly used in health services research to minimize coding 
errors.34,35 Conversely, some insured persons with CF who were mildly affected and had 
few CF-specific care episodes might not have met the case algorithm. On the other hand, the 
administrative prevalence of CF in the pediatric population in this study is consistent with 
the estimated birth prevalence of CF in the United States.4 A medical record review of 
children with billing codes for conditions at high risk of influenza (eg, asthma) found a 
sensitivity of 72% and specificity of 95%; the one case of CF was correctly coded.36
Third, and most seriously, information on health care use and expenditures is incomplete. 
For example, if patients obtain drugs through coupons from manufacturers and do not file a 
claim for reimbursement we have no record of those prescriptions. Most critically, rebates 
that health plans and pharmacy benefit managers receive from drug manufacturers at the end 
of the year can result in overstatement of net expenditures on drugs reported in payments 
recorded to pharmacies.29,37 Overall, net revenues of manufacturers after rebates and 
discounts in 2016 were 28.2% less than gross revenues.37,38 Not only do private plan 
expenditures on prescription medications appear overstated using administrative claims data, 
but the overstatement may be growing over time. From 2015 to 2016, aggregate national 
spending on medications calculated using invoice prices rose by 5.8% but after taking into 
account manufacturer rebates and other discounts it rose by just 4.8%.38
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We did not censor patients who received lung transplants. In 2016, 2% of continuously 
enrolled patients (n = 58) had received a lung transplant at some point during 2010–2016. 
Their mean and median expenditures during 2016 were $667 012 and $515 750, 
respectively. Excluding those patients reduced mean expenditures for the remaining patients 
by 5%.
5 | CONCLUSIONS
Rapid growth in private expenditures for CF in recent years appears to be largely due to 
increases in specialty drug spending, particularly as new high-priced precision medicine 
therapies are being introduced. Expenditures on the treatment of CF in the United States, as 
assessed through administrative private insurance claims, is increasingly dominated by 
specialty drugs. Ongoing evaluation of the benefits of existing and new therapies, as well as 
how they affect overall healthcare use, is needed to ensure patients receive high-quality, 
high-value care. A challenge for researchers, though, is a lack of accurate information as to 
how much payers are actually spending on CF medications after taking into account 
discounts and rebates.
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FIGURE 1. 
Mean Expenditures in 2016 US Dollars per Person with Cystic Fibrosis in MarketScan 
Commercial Data, 2010–2016. Expenditures are adjusted for inflation using the Personal 
Consumption Expenditures index, Bureau of Economic Analysis
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FIGURE 2. 
Distribution of Pharmacy Prescription Expenditures in 2016 US Dollars by Medication Type 
per Person with Cystic Fibrosis in MarketScan Commercial data, 2010–2016. 
Pharmaceutical spending by medication type in marketscan commercial data, 2010–2016
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